A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions

Advanced Malignant Tumor

Interventions

DRUG

HRS2398 Tablets

Take 5mg to 320mg once or twice a day ; Oral administration , 21 days as a cycle.

Trial Locations (1)

Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT05144061 - A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter